Amgen 2006 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2006 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

“We hope to find that denosumab
will be an important new
treatment option for patients
with bone metastases.”
“Denosumab appears to be a
completely new approach to
interfering with bone metabolism
in cancer.”
Guenther Steger, M.D., Medical University of Vienna
Since 1992, Dr. Steger has led the clinical breast cancer unit and
program for predictive factors at the Medical University of Vienna in
Austria. He is investigating a phase 3 clinical study of denosumab for
the treatment of bone metastases in advanced breast cancer.
Allan Lipton, M.D., Milton S. Hershey Medical Center College of Medicine,
Penn State University
Dr. Lipton and colleague Lois Witters have researched treatments for
cancer together since 1971. Their lab in Hershey, Pennsylvania,
administered denosumab to the first patient in the United States.
Amgen 2006 Annual Report 19